Fosgonimeton is an investigational new molecule being evaluated for the treatment of neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.
It is a pro-drug of the active metabolite dihexa, which binds to hepatocyte growth factor (HGF) and enhances its activity at the c-Met receptor. Fosgonimeton has shown neuroprotective effects in preclinical models, including reducing amyloid-beta toxicity and improving cognitive function in animal models of Alzheimer’s disease.
Clinical trials have demonstrated its safety and tolerability, with some evidence of potential cognitive benefits, though it failed to meet primary endpoints in a Phase 2/3 trial for Alzheimer’s.
The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
| Other Names | Fosgonimeton [INN], Fosgonimeton [USAN], H91OA9858J |
|---|---|
| IUPAC Name | [4-[(2S)-3-[[(2S, 3S)-1-[(6-amino-6-oxohexyl)amino]-3-methyl-1-oxopentan-2-yl]amino]-2-(hexanoylamino)-3-oxopropyl]phenyl] dihydrogen phosphate |
| CAS | 2093305-05-4 |
| Molecular Weight | 584.6 |
| Molecular Formula | C27H45N4O8P |
| SMILES | CCCCCC(=O)N[C@@H](CC1=CC=C(C=C1)OP(=O)(O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCCCCCC(=O)N |